Related Experiment Video

Updated: Apr 16, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.9K

The Role of Circulating Extracellular Vesicles in Hemophilia

Roza Chaireti1,2,3, Jovan P Antovic3,4, Iva Pruner5

  • 1Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.

Seminars in Thrombosis and Hemostasis
|April 14, 2026
PubMed

Hemophilia is a rare inherited bleeding disorder caused by a deficiency of factor VIII or IX, leading to insufficient thrombin generation and impaired clot formation. While advances in replacement and nonfactor therapies have improved patient outcomes, challenges such as inhibitor development, joint disease, and breakthrough bleeding persist. Extracellular vesicles (EVs) are small membrane-bound particles released from all kinds of cells and have emerged as key mediators of coagulation, vascular integrity, and immune responses. In hemophilia, EVs provide procoagulant surfaces, carry tissue factor and phosphatidylserine, and may stabilize clot structure, partially compensating for deficient coagulation. Clinical studies further suggest that EV levels and composition are altered by factor replacement or bypassing agents, indicating their role as biomarkers of treatment response. Beyond their diagnostic potential, engineered EVs are being explored as innovative therapeutic tools capable of delivering clotting factors and modulating joint inflammation. This review outlines current knowledge on circulating EVs in hemophilia, emphasizing their mechanistic roles, clinical evidence, and therapeutic potential.

More Related Videos

Isolation and Analysis of Traceable and Functionalized Extracellular Vesicles from the Plasma and Solid Tissues09:57

Isolation and Analysis of Traceable and Functionalized Extracellular Vesicles from the Plasma and Solid Tissues

Published on: October 17, 2022

2.9K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.4K

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Overview of Exosomes01:36

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
4.0K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.5K
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
18.9K